Trial Profile
Phase II trial of HPP 593 for the prevention of muscle weakness associated with prolonged mechanical ventilation (PMV) and critical injury
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 20 Jan 2016
Price :
$35
*
At a glance
- Drugs Mavodelpar (Primary)
- Indications Muscle weakness
- Focus Therapeutic Use
- 20 Jan 2016 New trial record